

Breaking the Seal...


Will Krost, MD, MBA, NRP
 Paramedic and EMS Medical Director
 Emergency Physician and Flight Physician
 Bon Secours Mercy Health Emergency Medicine and Life Flight
 Toledo, Ohio

1


Kidney Functions

- Removal of toxins, metabolic wastes, and excess ions from the blood
- Regulation of blood volume, chemical composition, and pH
- Gluconeogenesis during prolonged fasting
- Endocrine functions
 - Renin: regulation of blood pressure and kidney function
 - Erythropoietin: regulation of RBC production
- Activation of vitamin D


2



3




4



5

Nephrons




~1 million per kidney

6

Glomerular Filtration

- Passive mechanical process driven by hydrostatic pressure
- Governed by (and directly proportional to)
 - Total surface area available for filtration
 - Filtration membrane permeability
 - Net filtration pressure
 - Particle size
 - Charge on the particle




7

Glomerular Filtration


- Passive mechanical process driven by hydrostatic pressure - primarily
- Indirectly measured by creatinine and creatinine clearance calculation

| Stage of Disease | Description | GFR* (mL/min per 1.73 m ²) |
|------------------|--|--|
| 1 | Kidney damage with normal or increased GFR | ≥90 |
| 2 | Kidney damage with mildly decreased GFR | 60-89 |
| 3 | Moderately decreased GFR | 30-59 |
| 4 | Severely decreased GFR | 15-29 |
| 5 | Kidney failure | <15 (or undergoing dialysis) |



8

Glomerular Filtration



Net filtration pressure (10 mm Hg) = Glomerular hydrostatic pressure (60 mm Hg) - Bowman's capsule pressure (18 mm Hg) - Glomerular oncotic pressure (32 mm Hg)

Har. Guyton and HR. Textbook of Medical Physiology, 12th Edition Copyright © 2011 by Elsevier All rights reserved.

9


Opposite forces affecting GFR

- Prostaglandin E₂
 - Vasodilator that counteracts vasoconstriction by norepinephrine and angiotensin II
 - Prevents renal damage when peripheral resistance is increased

10


BUN:Creatinine ratio

(in the setting of renal failure / elevated creatinine)



- Pre-renal** (marked decrease in renal blood flow)
 - >20:1
 - Heart failure
 - Shock
 - Blood loss
- Renal**
 - <10:1
 - Infections
 - Toxins/Drugs
 - Direct trauma
- Post-renal** (obstruction of urine outflow from the kidney)
 - 10-20:1
 - Urinary tract obstructions

11




Primary regulators: ↓ Blood volume and/or blood pressure → ↓ GFR in blood → Brain → Vasoconstricting effect → Efferent arterioles vasoconstriction.

Other factors: Stress → ↑ Blood pressure and/or blood volume → Heart → ↑ Renin → Angiotensinogen (liver) → AT1 → ACE in the lungs → ATII → ADH and Aldosterone.


Effects of Angiotensin II:

- Vasoconstriction
- ADH release from...?
- CNS thirst response
- ↑ reabsorption of Na⁺ and water, ↑ reabsorption of glucose
- Na/H exchanger
- Inhibitory effect of adrenal cortex → Inhibits secretion of aldosterone → Targets kidney tubules


12



13



14



15

Major causes of Kidney Failure

- Prerenal Disease
- Vascular Disease
- Glomerular Disease
- Interstitial/Tubular Disease
- Obstructive Uropathy

16

Prerenal Disease

- Reduced renal perfusion due to volume depletion and/or decreased perfusion
- Caused by:
 - Dehydration
 - Volume loss (bleeding)
 - Heart failure
 - Shock
 - Liver disease

17

Vascular Disease

- **Acute**
 - Vasculitis – Wegener’s granulomatosis
 - Thromboembolic disease
 - TTP/HUS
 - Malignant hypertension
 - Scleroderma renal crisis
- **Chronic**
 - **Benign hypertensive nephrosclerosis**
 - Intimal thickening and luminal narrowing of the large and small renal arteries and the glomerular arterioles usually due to hypertension.
 - Most common in African Americans
 - Treatment:
 - Hypertension control
 - **Bilateral renal artery stenosis**
 - should be suspected in patients with acute, severe, or refractory hypertension who also have otherwise unexplained renal insufficiency
 - Treatment:
 - Medical therapy, surgery, stents.

18

Glomerular Disease

- Nephritis
 - Inflammation seen on histologic exam
 - Active sediment: Red cells, white cells, granular casts, red cell casts
 - Variable degree of proteinuria (< 3g/day)
- Nephrotic
 - No inflammation
 - Bland sediment: No cells, fatty casts
 - Nephrotic range proteinuria (>3.5 g/day)
 - Nephrotic syndrome = proteinuria + hyperlipidemia + edema

19

AKI: Medication Induced

- Diuretics
- NSAIDS
- Contrast media
- ACE inhibitors
- Antibiotics
 - Vancomycin, Gentamicin, Quinolones, Nitrofurantoin, Cephalosporins

20

Chronic Renal Failure

- Is a gradual & irreversible deterioration
- Usually not diagnosed until 75% of function is lost
- Causes
 - Diabetes mellitus 43%
 - Hypertension 26%
 - Inflammatory, immunological, or hereditary diseases
 - May follow acute failure

21

Consequences

- Nephrons enlarge to compensate
- Overburdened nephrons degenerate
- End-stage renal disease occurs

| Stage of Disease | Description | GFR* (mL/min per 1.73 m ²) |
|------------------|--|--|
| 1 | Kidney damage with normal or increased GFR | ≥90 |
| 2 | Kidney damage with mildly decreased GFR | 60–89 |
| 3 | Moderately decreased GFR | 30–59 |
| 4 | Severely decreased GFR | 15–29 |
| 5 | Kidney failure | <15 (or undergoing dialysis) |

22

Remember this...

- Fat (lipid) soluble
 - Basic pH (NH₃⁺ to NH₂)
 - Can cross membranes
 - Uncharged (neutral)
 - Non-polar
 - Lipophilic
 - Processed by liver
 - Nuclear or cytoplasmic receptors
 - Requires carrier protein
 - Long half-life
 - High volume of distribution
 - Small molecule
- Water soluble
 - Acidic pH (COOH to COO⁻)
 - Does not cross membranes
 - Charged
 - Polar
 - Hydrophilic
 - Processed by kidneys
 - Cell surface receptors
 - Has no carrier protein
 - Short half-life
 - Low volume of distribution
 - Large molecule

26

Steroids

- Mechanism of Action "I-KISS"
 - I – Inhibits Phospholipase A₂
 - K – Kills T Cells and Eosinophils
 - I – Inhibits Macrophage Migration
 - S – Stabilizes Mast Cells
 - S – Stabilizes Endothelium

27

27

Steroids

■ Mechanism of Action "I-KISS"

- I - Inhibits Phospholipase A₂

28

28

Steroids

■ Mechanism of Action "I-KISS"

- K - Kills T Cells & Eosinophils
- I - Inhibits Macrophage Migration
- S - Stabilizes Mast Cells
- S - Stabilizes Endothelium

29

29

Renal drugs

30

30

EFFECTS OF ACID-BASE DISTURBANCES on K⁺

Alkalosis = HypoK

H⁺ leaves the cells and enters the blood
K⁺ enters the cells and leaves the blood

Acidosis = HyperK

H⁺ leaves the blood and enters the cells
K⁺ leaves the cell and enters the blood

+ for +

31

31

Effects of loop & thiazide diuretics on K⁺

- Net effect: ↑K excretion → hypokalemia
- Loop diuretics block Na-K-2Cl co-transporters
- Thiazide diuretics block Na-Cl co-transporter
 - ↑Na⁺ delivery to the principal cells in the CD → ↑Na⁺ diffusion into the cells via luminal membrane → ↑Na⁺ pumping out of the cell by Na-K ATPase → ↑K⁺ influx into the cell & K⁺ into urine

32

32

Renal Pharmacology

Osmotic Diuretics

- Mannitol (Osmitol)

- Increases Urine Output
- Increases Fluid Osmolarity in Tubules

33

33

Renal Pharmacology

Loop Diuretics

- Furosemide (Lasix)/ Ethacrynic Acid/ Bumex
 - Inhibit Na/K/2Cl in the Thick Ascending limb of the Loop of Henle
 - Stimulates the Release of PGE
 - Action of PGE Inhibited by NSAIDS
 - Ethacrynic Acid- Does NOT have Sulfur

34

EFFECTS OF K-SPARING DIURETICS ON K+ EXCRETION

- Do not cause K+ loss via urine
- Mechanism: inhibition of stimulatory effect of aldosterone on Na+ reabsorption and K+ secretion

35

Hyper K- Cardiac Arrhythmia's - ECG changes

TREAT THE HYPER-K+ and Resuscitate per ACLS if pulseless

36

Hyper K- Cardiac Arrhythmia's

- Ventricular dysrhythmias
- Asystole

K+ is the problem...
High levels of K+ will cause the heart to become more positive and closer to threshold and ultimately prolong repolarization leading to a long QT.

37

ACUTE management

ACUTE HYPERKALEMIA

Rule-out false positive (STAT potassium)

ED MANAGEMENT KEYS

- Stop all Medications that can cause hyperK
- Monitor HCO3- resp, INET BOLUSES
- Consider re-binding Calcium
- If removal of K+ is not accomplished in the ED, repeat any Potassium-lowering therapies

ONLY WAY TO RID THE BODY OF K+ = Dialysis, Perfusion, Kayexalate

CKD = DIALYSIS KAYEXALATE

| | | | |
|--|---|--|--|
| <p>Calcium</p> <p>Drug: Calcium Gluconate</p> <p>MOA: competes with K+</p> <p>Dose: 5-10mM</p> <p>Duration: 30-60 min</p> <p>Dose: 100mg (10mM of 10%)</p> <p>Drug: Calcium Chloride (elemental)</p> <p>MOA: competes with K+</p> <p>Dose: 5-10mM</p> <p>Duration: 30-60 min</p> <p>Dose: 100mg (10mM of 10%)</p> | <p>Bicarbonate</p> <p>Drug: Sodium Bicarbonate</p> <p>MOA: increases Na/K ATPase activity - moves K+ intracellularly</p> <p>Dose: 50-100 mg (oral)</p> <p>Duration: 30-60 min</p> <p>Dose: 10-20mg in 100ml of water over 15-30 min (IV) (use 10% standard bicarbonate dose)</p> <p>MOA: may also give 10% solution of 0.1% NaCl pH adjustment</p> | <p>Beta-2 Agonists</p> <p>Drug: Albuterol</p> <p>MOA: increases Na/K ATPase activity - moves K+ intracellularly</p> <p>Dose: 2-4 mg</p> <p>Duration: 30-60 min</p> <p>Dose: 2.5mg IV (10mg of 100mg/10ml) (10mg of 100mg/10ml)</p> <p>MOA: increases Na/K ATPase activity - moves K+ intracellularly</p> <p>Duration: 30-60 min</p> <p>Dose: 2-4 mg</p> | <p>Resins (K+ binders)</p> <p>Drug: Kayexalate (patirolone)</p> <p>MOA: binds K+, Ca++, and Mg++ and excretes in stool</p> <p>Dose: 10-20mg (oral)</p> <p>Duration: 1-2 hours</p> <p>Dose: 200mg (oral) (100mg of 50% solution) (2-4 hours)</p> <p>MOA: binds K+ and excretes in stool</p> <p>Duration: 1-2 hours</p> <p>Dose: 200mg (oral) (100mg of 50% solution) (2-4 hours)</p> |
|--|---|--|--|

38

ACUTE management

- Calcium for HyperK
 - Interferes with the excessive excitation caused by K+
 - Blocks the K+ channels
 - CaCl in adults,
 - CaGluconate in peds

Only use Ca++ if the QRS is wide!

$$V_m = \frac{RT}{F} \ln \left(\frac{p_K [K^+]_o + p_{Na} [Na^+]_o + p_{Cl} [Cl^-]_i}{p_K [K^+]_i + p_{Na} [Na^+]_i + p_{Cl} [Cl^-]_o} \right)$$


Goldman Hodgkin Katz equation

39

ACUTE management

- Insulin/Glucose
 - Insulin stimulates the Na/K pump and increases it's activity. Moving K+ into the cell.
 - Glucose will correct any hypoglycemia associated with the insulin administration
- Albuterol
 - The Beta 2 properties increase activity of the Na/K pump and move K+ into the cell.

Check BGL levels – Glucose is not necessary in a hyperglycemic patient



40

ACUTE management

- Bicarbonate
 - Works on the H+/K+ exchange mechanism
 - As HCO₃⁻ is added to the blood, H+ will leave the cell in an attempt to buffer the alkaline load and force K+ to move into the cell to balance the ICF charge.
- 3 D's
 - The ONLY ways to REMOVE excess K+
 - Dialysis
 - Diarrhea (induced)
 - Kayexalate
 - Diuresis
 - Bolus with NaCl and administer a diuretic simultaneously

41

Hypernatremia

- Etiology
 - Dehydration
 - Water deprivation
 - Dietary intake
- Pathophysiology
 - net water loss or a sodium gain
- S/Sx
 - Intense thirst
 - HTN
 - Edema
 - Agitation
 - Convulsions

42

Hyponatremia


- Etiology
 - Excessive water intake
 - chronic vomiting or diarrhea,
 - Aldosterone deficiency
 - Dietary is rare
 - Diuretics
- Pathophysiology
 - Cellular edema
- S/Sx
 - Muscle weakness
 - dizziness
 - Hypotension
 - tachycardia
 - Altered mentation

43


ACUTE management

- **Hypernatremia**
- Acute Change in Na (occurred within 24 hours)
 - correct the serum sodium at rate of 2-3 mEq/L/h (maximum total, 12 mEq/L/d)
- Progressive change in Na – chronic sodium imbalance
 - corrected at a rate not to exceed 0.5 mEq/L/h and a total of 8-10 mEq/day
- If HYPERvolemic, salt and water restriction plus diuretics and V2 antagonists (ADH blockers)
- **Hyponatremia**
- Acute Change in Na (occurred within 48 hours)
 - Overtly symptomatic pt (Sz) will be treated with 3% (hypertonic saline).
- Progressive change in Na – chronic sodium imbalance
 - Free water restriction (<1 L/day)
- If HYPERvolemic, salt and water restriction plus diuretics and V2 antagonists (ADH blockers)


44




45




46



47



48



49

Cardiac Physiology

| | | |
|------------|---|---|
| α_1 | \uparrow TPR = \uparrow preload | \uparrow Venous Return = \uparrow afterload |
| β_1 | \uparrow HR, conduction | \uparrow contraction, automaticity |
| α_2 | \downarrow NE Synthesis | \downarrow NE release |
| β_2 | \downarrow TPR = \downarrow preload | \downarrow Venous Return = \downarrow afterload |

50

Cardiac Pharmacology

Class I - Na⁺ Channel Blockers

- Class 1A
 - Procainamide, Disopyrimide, Quinidine
- Class 1B
 - Mexiletene, Lidocaine, Tocainide, Phenytoin
- Class 1C
 - Encainide, Flecainide, Propafenone

Ventricular Action Potential

- Class IA: e.g., quinidine
 - Moderate Na⁺-channel blockade
 - 75%
- Class IB: e.g., lidocaine
 - Weak Na⁺-channel blockade
 - 80%
- Class IC: e.g., flecainide
 - Strong Na⁺-channel blockade
 - 85%

51

Cardiac Pharmacology

Class II – Beta Blockers

- **Cardioselective:**
 - Diltiazem (Cardizem)
 - Verapamil
- **Vasoselective**
 - "Pines"
 - Nicardipine
 - Nimodipine

52

52

Cardiac Pharmacology

Class III – Potassium Channel Blockers

- **Amiodarone**
 - Contains elements of all class
 - Class I, II, III, IV
- **Sotalol**
 - Contains Class II and III

53

53

Cardiac Pharmacology

Class IV – Calcium Channel Blockers

- **Cardioselective:**
 - Diltiazem (Cardizem)
 - Verapamil
- **Vasoselective**
 - "Pines"
 - Nicardipine
 - Nimodipine

- Decreases Action Potentials in the atria and thalamus
- Increases PR Interval
- Decreases smooth muscle tone

Absence seizures?
Where do they originate

54

54

Cardiac Pharmacology

Other Anti- Arrhythmics

- **Digoxin**
 - Inhibits Na/K ATPase
 - Indirectly Inhibits Na⁺/Ca²⁺ Exchange
- **Clinical Use:**
 - CHF
 - Atrial Fibrillation

55

55

Cardiac Pharmacology

Vasopressors

Vasopressors

Phenylalamine

↓

Tyrosine

↓

L-Dopa

↓

Dopamine

↓

Norepinephrine

↓

Epinephrine

56

56

Cardiac Pharmacology

Vasopressors

- **Norepinephrine**
 - Septic Shock
 - Distributive shock after volume replacement
- **Dobutamine**
 - Cardiogenic shock
- **Dopamine**
 - Refractory Sepsis or cardiogenic shock
- **Epinephrine**
 - Refractory Shock or cardiogenic shock

57

57

Cardiac Pharmacology

Vasopressors

- Norepinephrine
 - α_1 +++++
 - β_1 + + +

| | | |
|------------|-------------------|-------------------------------|
| α_1 | ↑ TPR = ↑ preload | ↑ Venous Return = ↑ afterload |
| β_1 | ↑ HR, conduction | ↑ contraction, automaticity |
| α_2 | ↓ NE Synthesis | ↓ NE release |
| β_2 | ↓ TPR = ↓ preload | ↓ Venous Return = ↓ afterload |

58

Cardiac Pharmacology

Vasopressors

- Dobutamine
 - β_1 + + +
 - β_2 +

Lower HR effect then Dopamine

| | | |
|------------|-------------------|-------------------------------|
| α_1 | ↑ TPR = ↑ preload | ↑ Venous Return = ↑ afterload |
| β_1 | ↑ HR, conduction | ↑ contraction, automaticity |
| α_2 | ↓ NE Synthesis | ↓ NE release |
| β_2 | ↓ TPR = ↓ preload | ↓ Venous Return = ↓ afterload |

59

Cardiac Pharmacology

Vasopressors

- Dopamine
 - α_1 ++ (10-20 μ /Kg/Min)
 - β_1 + + + (5-10 μ /Kg/Min)
 - β_2 +
 - DA ++ (0.5-5 μ /Kg/Min)

| | |
|--|---|
| Dopamine Receptors <small>Renal, Mesenteric & coronary (pulmonary circulation, heart)</small> 1-5 mcg/kg/min | <ul style="list-style-type: none"> • Vasodilation in kidney? • Increase in CO? • Direct renal-vascular effects? • Positive inotropic? • Endocrine effects? |
| Alpha Receptors <small>More homogeneously distributed</small> 3-15 mcg/kg/min | <ul style="list-style-type: none"> • Vasoconstriction? • Positive inotropic? • Metabolic effects? |
| Beta Receptors <small>More homogeneously distributed</small> 15-50 mcg/kg/min | <ul style="list-style-type: none"> • Positive inotropic? (direct and indirect) • Positive chronotropic? • Peripheral vasodilation • Metabolic effects? |


| | | |
|------------|-------------------|-------------------------------|
| α_1 | ↑ TPR = ↑ preload | ↑ Venous Return = ↑ afterload |
| β_1 | ↑ HR, conduction | ↑ contraction, automaticity |
| α_2 | ↓ NE Synthesis | ↓ NE release |
| β_2 | ↓ TPR = ↓ preload | ↓ Venous Return = ↓ afterload |

60

Cardiac Pharmacology

Vasopressors

- Epinephrine
 - α_1 ++
 - β_1 + + +
 - β_2 +



Inject the full 1 mg into a 1,000 mL normal saline bag (final concentration 1 mcg/mL).

Push-dose or dirty gtt is a great interim strategy

| | | |
|------------|-------------------|-------------------------------|
| α_1 | ↑ TPR = ↑ preload | ↑ Venous Return = ↑ afterload |
| β_1 | ↑ HR, conduction | ↑ contraction, automaticity |
| α_2 | ↓ NE Synthesis | ↓ NE release |
| β_2 | ↓ TPR = ↓ preload | ↓ Venous Return = ↓ afterload |

61

THANK YOU!!

wkrost@gwu.edu

62